Background: Animal studies suggest that N-methyl-D-aspartate receptor (NMDAR) hypofunction and subsequent decline in intracellular nitric oxide (NO) are responsible for development of ketamine-induced psychedelic symptoms. To examine this mechanism in humans, we administered the NO donor sodium nitroprusside during infusion of racemic ketamine (RS-ketamine), containing equal amounts of S(þ)-and R(e)-ketamine isomers, or esketamine, containing just the S(þ)-isomer. Methods: In this randomised, double blind, placebo-controlled crossover study, healthy volunteers were treated with
Editor's key points
Reduced neuronal nitric oxide signalling has been implicated in the psychotogenic symptoms of ketamine administration. The ability of sodium nitroprusside to reduce the psychedelic symptoms of ketamine was tested in human volunteers. Sodium nitroprusside reduced the drug high and the psychedelic symptoms of racemic RS-ketamine but not of S-ketamine infusion. Reduced nitric oxide signalling is involved in the psychedelic symptoms of RS-ketamine, while the mechanism of the effects of S-ketamine requires further study.
Ketamine, a non-competitive antagonist of the N-methyl-Daspartate receptor (NMDAR), was designed in the 1960s as a shorter acting alternative to phencyclidine. 1 While initially applied as an anaesthetic in clinical human and veterinarian practice, it is currently also used off-label for treatment of acute and chronic non-cancer pain, opioid-refractory cancer pain, migraine, post-traumatic stress disorder, and major (therapy-resistant) depression. 1e7 Despite its efficacy for multiple indications, physicians are sometimes hesitant when considering ketamine treatment, and patient compliance can be low because of undesirable symptoms. 2, 8 In rodents, NMDAR antagonists produce hyperlocomotion, stereotypical or psychotic-like behaviour (including increased urge to run around, inability to hold still with weaving/shaking/twitching of the head and body), and ataxia 9 ; in humans, ketamine induces schizotypical or psychedelic effects (paranoia, hallucinations, derealisation, depersonalisation, anxiety) and an intense state of (drug) high. 2, 8 As these symptoms mimic schizophrenic behavioural effects, ketamine is successfully used in volunteers as model of schizophrenia. 10, 11 Although in patients psychedelic symptoms can be moderated with benzodiazepine or a 2 -agonist treatment, complete disappearance occurs when treatment ends. 2, 8 Several mechanisms have been proposed to explain the psychedelic effects caused by ketamine and related NMDAR antagonists, such as decreased gamma-aminobutyric acid B receptor function or altered dopaminergic transmission. 12e14 An attractive hypothesis relates to the model of NMDAR hypofunction. Ketamine binds to the phencyclidine site of the NMDAR, which blocks the inflow of Ca 2þ -ions. 1, 15 Normally, Ca 2þ -ions that enter the cell in response to glutamatergic NMDAR activation bind to calmodulin that subsequently stimulates nitric oxide (NO) synthase to produce the gaseous neuromodulator NO from L-arginine.
16e18 NO interacts with guanylyl cyclase to generate cyclic guanosine monophosphate (cGMP) from guanosine triphosphate; cGMP subsequently interacts with cGMP-dependent protein kinase and has neuroplastic, neurotrophic, and neuroprotective effects. -ion inflow reduces intracellular NO synthesis. 19 Animal studies show that modulation of NO concentrations using mechanisms that bypass the NMDAR can reduce or even prevent NMDAR hypofunction-related psychotic behaviour. For example, in mice and rats, the NO donor sodium nitroprusside blocks phencyclidine-and racemic ketamine-induced psychotic behavior. 20, 21 Additionally, sodium nitroprusside can attenuate racemic ketamine-induced memory defects and social withdrawal and has anxiolytic effects. 22 In a recent human study, improvement of schizophrenia symptoms was observed after nitroprusside treatment. 23 To determine whether NMDAR antagonist-induced psychedelic symptoms are amendable by modulation of the nitrinergic pathway in humans, we tested the effect of sodium nitroprusside i.v. in a healthy population during the infusion of increasing doses of ketamine. Psychedelic effects were measured using the Bowdle questionnaire, a validated list of 13 questions developed for quantifying the psychedelic effects of ketamine in healthy volunteers. 24, 25 We applied our paradigm to two ketamine formulations that are currently commercially available for human use, racemic ketamine and esketamine. Racemic ketamine contains equal amounts of two optical isomers, the S(þ)-and R(e)-enantiomers; esketamine exclusively contains the S(þ)-isomer. Our approach will allow detection of nitroprusside effects specific to S(þ)-ketamine, R(e)-ketamine or to both enantiomers. We hypothesise that nitroprusside reduces racemic ketamine-and esketamineinduced drug high (our main end-point) and changes in internal and external perception (secondary end-points).
Methods

Ethics
Participants were recruited after protocol approval was obtained from the Human Ethics Committee at Leiden University Medical Centre (Leiden, The Netherlands) and the Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek, The Hague, The Netherlands) by flyers posted on the Leiden University campus. All subjects gave oral and written informed consent before participation in the study. The study was registered in the Dutch trial register (www.trialregister.nl) under number NTR 5359. This study is part of a large project on: (1) the pharmacokinetics and pharmacodynamics of racemic ketamine vs esketamine and; (2) the influence of sodium nitroprusside on ketamine's effects (psychedelic effects, mood, cardiovascular effects, and pain relief). Here we report on the effect of sodium nitroprusside on the psychedelic effects of the two ketamine formulations currently commercially available.
Subjects
Male subjects, aged 18e34 yr and with a BMI of 30 kg m À2 or less, were recruited. Participation was possible after passing a physical examination and after reported absence of any health issues including presence or history of any psychiatric, medical or neurologic disorder, presence or a history of illicit drug use or excessive alcohol consumption (>21 units per week), or known allergies to study medication. Additionally, subjects were excluded from participation if they had a positive drug screen on the day of screening or on any of the study days, had participated in another trial in the 3 months before enrolment, or used any medication on a regular basis (e.g. pain medication). The decision to enrol the subject into the study was made by the independent physician that performed the subjects' screening. Subjects were asked to refrain from food or drinks for 8 h before dosing, not to consume caffeinated food or beverages in the 24 h before dosing, and not to consume any grapefruit-containing food or beverages during the 7 days preceding the study day.
On each occasion, upon arrival in the laboratory, two i.v. access lines were placed in the large veins of the arm, one for administration of ketamine (racemic ketamine or esketamine) and the other for infusion of nitroprusside or placebo. An arterial line was placed in the left or right radial artery to continuously monitor blood pressure and allow arterial blood sampling. Blood samples were not used in the analysis of the current study. Subjects were monitored by ECG, oxygen saturation was measured via a finger probe, and blood pressure through an arterial line.
Study design
This was a placebo-controlled double blind randomised crossover proof-of-concept study with acronym SNIK. Subjects were studied on four occasions that were identical in study performance except for the medication administered. On occasions A and B, subjects received a dose-escalation of i.v. racemic ketamine (Ketalar for 1 h, followed by 0.57 mg kg À1 h À1 for another hour and finally 1.14 mg kg À1 h À1 for the last hour of ketamine administration ( Fig. 1 ). The equivalent administered esketamine doses were 0.14 mg kg À1 h À1 for 1 h, followed by 0.28 mg kg À1 h À1 for another hour and finally 0.57 mg kg À1 h À1 for the last hour of ketamine administration ( Fig. 2) . The two-fold difference in racemic ketamine and esketamine dose was based on data from the literature indicating that S(þ)-ketamine is twice as potent as the racemic mixture, 26 and a pilot study in which we infused 50 mg racemic ketamine or esketamine per hour in six subjects and measured psychedelic symptoms. The effects observed during 50 mg esketamine infusion were more intense by a factor of two than those observed during racemic ketamine infusion, as based on the area-under-the-curve (AUC) of the visual analogues scores of the different psychedelic end-points (data not shown). Reduction of the esketamine dose would reduce the chance that blinding would be broken because of differences in effect sizes.
Randomisation, blinding, and monitoring
A computer-generated randomisation list with a four-block design was generated from www.randomization.org by a study manager (not involved in the execution of the study) on June 11, 2015. The list was sent to the local pharmacy and after subject allocation, medication was prepared according to Good Manufacturing Practice. Study medication was prepared on the study day and dispensed to the study team before dosing. The study was double blind for ketamine (racemic ketamine vs esketamine) and nitroprusside (nitroprusside vs placebo) treatments. All medications were prepared by the pharmacy in 50 ml syringes marked with (coded) subject and visit numbers. Nitroprusside and placebo (but not ketamine) syringes were covered with foil to prevent inactivation of nitroprusside by ambient light. The research team remained blinded to study medication until all data were collected (August 24, 2017). The study was independently monitored and data analysis was performed after the monitor had filed the final report (September 29, 2017) ensuring that all Good Clinical Practice requirements were met.
Measurements
We queried subjects at regular intervals regarding the occurrence of ketamine side effects before, during, and after drug infusion using the Bowdle questionnaire (at baseline, i.e. before any drug administration, and at t¼20, 40, 55, 80, 100, 115, 140, 160, 175, 200, 220, 240, 260, and 280 min after start of racemic ketamine or esketamine infusion; Fig. 1 ). The questionnaire uses a visual analogue scale (VAS) to indicate the severity of effects or feelings reported by the subject.
24,25
The Bowdle questionnaire evaluates three psychedelic ketamine effects, drug high and changes in internal and external perception, from 13 questions scored on a 100-mm VAS scale from zero (no effect) to 100 (maximum effect). 24, 25 Drug high is derived from question 11 of the questionnaire (Supplementary  Table S1 ). Internal perception reflects inner feelings that do not agree with reality; it is derived from questions on unrealistic voices or sounds, unrealistic thoughts, and paranoid or anxious feelings (questions 4, 5, 8, 9, 10, 13). The external perception indicates a misperception of external stimuli or the surroundings; it is derived from questions on body parts, surroundings, the passing of time, and the perception of colour and sound (questions 1, 2, 3, 6, 7). The list of Bowdle questions is given in Supplementary Table S1 .
Sample size, data analysis, and data validation
As we had no indication from the literature what the magnitude of effect of nitroprusside would be on ketamine's psychedelic effects, we assumed that nitroprusside would reduce the drug high AUC by 20% [e.g. a reduction from 8000 to 6400 with standard deviation (SD) 1600], whereby we would need 17 subjects to detect an effect with power greater than 80% and alpha of 0.05. We reasoned that a 20% reduction in effect would be clinically relevant. A sample size of 20 was chosen to take subject withdrawal into account. Nitroprusside effects of ketamine-induced psychedelic symptoms -1011
The area-under-the time-effect curves (AUC) for drug high (the main end-point of the study), internal and external perception were calculated. The effect of nitroprusside was calculated separately for racemic ketamine and esketamine.
The effect of nitroprusside was tested by paired two-sided ttests or non-parametric tests using GraphPad Prism version 7 for MAC OS X, GraphPad Software (La Jolla, CA, USA); P-values <0.05 were considered significant.
An internal validation of data was obtained by performing 100 000 bootstrap simulations and calculating the 95% confidence intervals of the AUCs. The validation process was performed in R (The R Foundation for Statistical Computing, www.r-project.org, accessed October 27, 2017).
Results
Thirty-five subjects were recruited (see consort flow chart in Fig. 2 ); 14 withdrew from the study for various reasons [ketamine side effect too intense (n¼5), ketamine-induced tachycardia (n¼1), did not show up on the first visit (n¼4), withdrew consent after screening (n¼2), other reasons (n¼2)]. One subject could not participate because of the inability to place the arterial line. Twenty subjects completed the four experimental sessions. The questionnaire data from three subjects were discarded as they were deemed unreliable because of protocol violations (subjects did not score the psychedelic effects according to instructions). As the remaining number of subjects was similar to our intended sample size, we did not recruit additional subjects. Hence, data from 17 male subjects were analysed. À2 . All completed the study without major side effects. Nitroprusside had no effect on any of the measured psychedelic end-points as all scores obtained during infusion, but before any ketamine administration were zero or close to zero (Figs 3e5). Additionally, there was no systematic occurrence of side effects related to just nitroprusside, such as flushing or headaches, before infusion of racemic ketamine or esketamine.
Drug high
Compared with placebo, nitroprusside significantly reduced the sensation of high (Fig. 3) during infusion of racemic ketamine (effect size 22%, P¼0.02, Table 1 ) but not during infusion of esketamine (effect size 8%, P¼0.65). The racemic ketamine AUC observed during treatment with nitroprusside reached values close to those of esketamine (AUC racemic ketamine/ nitroprusside vs AUC esketamine/placebo: P¼0.27; AUC racemic ketamine/nitroprusside vs AUC esketamine/nitroprusside: P¼0.67). The scatter plots show the difference in effect of nitroprusside with 13 subjects (76%) that showed a decrease in racemic ketamine drug high AUC while the effect on esketamine AUC was equivocal with eight of 17 subjects (47%) showing a decrease in drug high with nitroprusside treatment.
Internal perception
We observed a 43% reduction by nitroprusside relative to placebo of the internal perception AUC during racemic ketamine infusion (Fig. 4 ; P<0.01). During infusion of esketamine, nitroprusside did not affect the AUC (P¼0.26). Twelve subjects showed a reduction in psychedelic effects from racemic ketamine against six subjects from esketamine (Fig. 4B ).
External perception
Compared with placebo, nitroprusside significantly reduced external perception AUC (Fig. 5 ) during infusion of racemic ketamine (effect size 30%, P¼0.02, Table 1 ) but not during infusion of esketamine (effect size À6%, P¼0.83). Thirteen subjects had a nitroprusside-induced AUC reduction during racemic ketamine vs eight during esketamine infusion. The results of the interval validation are given in Supplemental Table S2 . These analyses confirm that nitroprusside had a significant effect on psychedelic effects induced by racemic ketamine, but not on effects induced by esketamine.
Discussion
Earlier rodent studies showed that the NO donor nitroprusside effectively eliminates psychedelic effects observed during ketamine and phencyclidine administration. 19, 20 Other manifestations of NMDAR blockade, such as memory impairment, are also reversed by modulation of the nitrinergic pathway, either by NO donation or by administration of the membrane permeant cGMP analogue 8-bromo-cGMP. 27, 28 We tested the hypothesis that modulation of the nitrinergic pathway through NO donation would also reduce psychedelic symptoms produced by blockade of the NMDAR in humans. We studied the effect of relatively low-dose nitroprusside infusion during treatment with the two commercially available ketamine formulations, racemic ketamine (containing equal amounts of the two isomers) and esketamine, the S(þ)-ketamine isomer. We observed that both formulations produced dose-dependent psychedelic symptoms that quickly resolved upon termination of the infusion. However, concomitant treatment with nitroprusside had a differential effect on the two isomers, with 20e40% less intense psychedelic effects experienced during racemic ketamine infusion but not during esketamine infusion. This indicates that nitroprusside has a divergent effect on S(þ)-and R(e)-ketamine-isomers. Our findings are in agreement with preclinical studies that used racemic ketamine to examine the mechanism of ketamine-induced psychosis.
20,21
Racemic ketamine vs esketamine
The differential effect of nitroprusside on the symptoms induced by the two ketamine formulations was unexpected.
The insensitivity of esketamine to nitroprusside suggests that our observations are restricted to an interaction of nitroprusside with R(e)-ketamine-induced NMDAR hypofunction. Both isomers interact with the NMDR but with different affinities: S(þ)-ketamine has a fourfold higher affinity for the NMDAR than R(e)-ketamine. 29, 30 Higher nitroprusside doses might be required to overcome the downstream consequences of NMDAR hypofunction induced by an isomer with a higher NMDAR affinity relative to R(e)-ketamine. We based the nitroprusside dose on a previous study that showed that 0.5 mg kg À1 h À1 nitroprusside given for 4 h is safe and effective in reducing acute symptoms in schizophrenia in humans. 23 We plan future studies on the effect of increasing nitroprusside doses on esketamine and racemic ketamine pharmacodynamics. This will establish whether the nitroprusside mechanism of action at (and beyond) the NMDAR is divergent for the two isomers, or whether our current observation is best explained by nitroprusside underdosing. With respect to the former theory, animal studies show that the S(þ)-and R(e)-ketamine isomers produce their antidepressant effects through different cellular pathways. 31, 32 We cannot exclude that different cellular pathways contributed to our observations. The lack of a trend in the effects of nitroprusside on esketamine-induced side effects suggests that the S(þ)-ketamine isomer induces its psychedelic effects through an NO-independent pathway. So far, no other mechanism of the psychedelic symptoms produced by the two ketamine isomers has been postulated. This might be related to the fact that all experimental work so far has been done with the racemic ketamine formulation. 20, 22 Although our study was not designed for a one-on-one comparison between isomers, our study protocol enables estimation of the potency difference between the two isomers by comparing their placebo AUC values. We assume that the AUC of the R(e)-isomer¼AUC racemic ketamineeAUC esketamine. The calculated R(e)-ketamine AUC was about half of the measured esketamine AUC, which implies a two-fold greater potency of the S(þ)-isomer compared with the R(e)- Nitroprusside-induced modulation of racemic ketamine psychedelic symptoms
Nitroprusside infusion reduced psychedelic effects induced by racemic ketamine, more specifically the R(e)-isomer, most likely through interaction within the NMDAR-Ca 2þ -calmodulin-NO synthase-NO-cGMP pathway. In line with animal studies, nitroprusside-induced increase in neuronal NO concentrations and consequently the NO-cGMP sequence reactivation could be responsible for the reduced intensity of behavioural effects that we observed in volunteers treated with racemic ketamine and nitroprusside. However, other mechanisms could play a role in the actions of nitroprusside, such as an inhibitory effect of NO on dopaminergic hyperfunction (independent of cGMP activity), 33 or direct nitroprusside effects. Examples of the latter are observations that nitroprusside itself can restore NMDAR hypofunction or improve function through neuroprotective and antiinflammatory mechanisms by interaction with nuclear factor-kB, a nuclear factor that controls DNA transcription.
34e36
Irrespective of the postulated mechanisms, the exact process by which NO modulates ketamine-induced psychedelic effects in humans cannot be deduced from our experiments and remains unknown. It is important to realise that in some animal models, reduced NOS activity is associated with reduced psychosis-like symptoms from phencyclidine or ketamine. 37, 38 This highlights the complexity of the NMDAR-NO interaction that is still insufficiently understood.
Clinical implications
The psychedelic symptoms associated with the use of ketamine led to reduced patient and doctor compliance in its use as an analgesic. 2, 8 We observed a 20e40% decrease in psychedelic effects by nitroprusside during racemic ketamine infusion. This is a moderate effect that might have a limited clinical importance. It is too early to consider nitroprusside a viable and clinically relevant addition to racemic ketamine treatment, in the sense that ketamine treatment might be better accepted and higher doses may be given to produce adequate and long-term analgesic effects. 2, 8 Further studies are needed (i) to corroborate our findings, (ii) to assess whether the reduction of psychedelic side effects can be increased above the current observation with higher nitroprusside doses, and (iii) to determine whether the ketamineinduced increases in blood pressure are reduced by nitroprusside. It is important to realise that in the treatment of depression, there is a suggestion that the dissociative effects of ketamine mediate its antidepressant effects. 39 Modulation of these effects by nitroprusside will then be counterproductive. Further (animal) studies are needed to determine the modulatory role of nitroprusside in ketamine treatment in depression. For now, as mood improvement is sometimes also desirable in the treatment of chronic pain patients, 40 the clinical use of nitroprusside in modulating the side effects of ketamine during pain treatment in chronic pain patients with depressive traits should only be practiced when other approaches fail (such as treatment with benzodiazepines or a 2 -agonist).
Critique of methods
As stated above, the lack of effect of nitroprusside during esketamine treatment could reflect the relatively low nitroprusside dose (0.5 mg kg À1 min À1 ) that we used in this study. In future studies, we will examine the effect of higher nitroprusside doses on the intensity of esketamine-induced psychedelic symptoms. However, one needs to realise that highdose nitroprusside (>2 mg kg À1 min À1 ), administered for longer periods of time, is associated with toxicity. Through interaction with oxyhaemoglobin, nitroprusside can form methaemoglobin and cyanide that can interfere with oxygen transport and cytochrome activity, respectively. 41, 42 We enrolled 35 subjects into the study and allocated treatment to 27 of them. We were able to analyse the data from just 17 subjects because of a variety of reasons. We used a relatively high dose of esketamine (0.3 mg kg À1 h À1 ) and racemic ketamine (0.6 mg kg À1 h À1 ), which is higher than we routinely use in clinical practice. This was done to maximise the drug high and other psychedelic symptoms. Because of the occurrence of side effects, five subjects prematurely ended their participation in the study. One subject experienced an episode of tachyarrhythmia (heart frequency >140 min À1 ) that required cessation of ketamine infusion. Additionally, three subjects either refused to score the intensity of psychedelic symptoms as requested, or failed to understand the scoring system. The latter was probably related to cognitive impairment during ketamine administration. We accept the high number of dropouts, but also believe that improved screening and coaching will reduce failure of successful study completion. As we continued recruitment until we had 17 reliable and complete data sets, we assumed that the high subject loss would not influence study outcomes. This was indeed confirmed by the internal validation of the data analyses.
Conclusions
In healthy male volunteers, the NO donor sodium nitroprusside significantly reduced the psychedelic symptoms of drug high and internal and external perception caused by racemic ketamine. No effects from nitroprusside were observed in volunteers treated with esketamine, the S(þ)-ketamine isomer, suggesting that the nitroprusside effect was directed at the NMDAR actions of the R(e)-isomer but not of the S(þ)-isomer. Possibly higher nitroprusside doses are needed to relieve the psychedelic effects from S(e)-ketamine which has a four-fold higher affinity for NMDARs than R(e)-ketamine. However, we cannot exclude that the two ketamine isomers produce their psychedelic symptoms through divergent cellular pathways. Finally, our proof-of-concept study requires further clinical proof in larger samples with higher nitroprusside doses (to produce greater effects than the current 20e40% reduction of psychedelic effects during racemic ketamine infusion) before we can implement nitroprusside treatment to counteract racemic ketamine-related psychedelic symptoms. 
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